Otsuka Pharmaceutical Company, Limited

Glycomimetics, Inc.

Indranath Ghosh

John L Magnani

Geraldine C Harriman

Kazumi Kondo

Masaki Suzuki

Akira Takahashi

Arun K Sarkar

Shin Miyamura

Takeshi Kuroda

Muneaki Kurimura

Amy M Elder

Satoshi Shimizu

Kevin J Hodgetts

John M Peterson

Haruka Takahashi

Jason S Newcom

Tae Fukushima

Yusufbhai U Vohra

Krishna Reddy Valluru

Abhishek Dogra

Jason Nogueira

Amy Elder

Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of galectin-3 to ligands are disclosed. For example, inhibitors of galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.

Galectin-3 inhibiting c-glycosides

Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands are disclosed. For example, heterobifunctional inhibitors of E-selectin and galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.

Heterobifunctional inhibitors of E-selectin and galectin-3

Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP), such as those of formula (III), and composition thereof are described herein. Exemplary disorders include schizophrenia and cognitive deficit. 

Therapeutic compounds and related methods of use

Compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat a disorder, e.g., schizophrenia and cognitive deficit, in a subject are described herein. The compounds disclosed herein include quinoline and quinazoline-containing compounds that modulate striatal-enriched tyrosine phosphatase (STEP) activity.

Growing community of inventors

Olney, MD, United States of America

Indranath Ghosh